Humacyte, Inc. (HUMA) Stock Forecast
HUMA analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 5 analysts
- Price target
- $1.62 average of analyst targets
- Upside to target
- +278.8% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.09
- 52-week range
- $0.35 – $1.81
HUMA analyst ratings
5 analystsNumber of analysts at each rating.
HUMA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HUMA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.10 | −$0.06 | −$0.11 | +25.0% | 4 |
| Current fiscal year (2026) | −$0.40 | −$0.46 | −$0.34 | −$0.26 | −53.8% | 4 |
| Next fiscal year (2027) | −$0.25 | −$0.30 | −$0.18 | −$0.40 | +38.1% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HUMA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $770,000 | $500,000 | $1.0M | +2.3% | 5 |
| Current fiscal year (2026) | $3.5M | $2.1M | $5.2M | +72.3% | 5 |
| Next fiscal year (2027) | $21.7M | $10.6M | $43.3M | +518.8% | 5 |
HUMA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HUMA revenue: reported and forecast
HUMA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.08 | −$0.08 | −$0.08 | −$0.08 | −1.0% | 1 up · 1 down |
| Current fiscal year (2026) | −$0.35 | −$0.40 | −$0.40 | −$0.40 | −$0.40 | +14.3% | 1 up · 2 down |
| Next fiscal year (2027) | −$0.24 | −$0.25 | −$0.25 | −$0.25 | −$0.25 | +3.1% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HUMA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HUMA beat in 6 of 12.
What analysts expect from HUMA
5 analysts cover Humacyte; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.62, 278.8% above the latest close of $0.43. Analysts expect earnings of −$0.40 per share for 2026, −53.8% from a year earlier. For 2027 the average estimate is −$0.25 per share on revenue of $21.7 million. Humacyte beat the EPS estimate in 6 of the last 12 quarters.
Related: HUMA income statement, HUMA key metrics, HUMA chart. See the HUMA stock overview for the latest quote and news.
HUMA forecast FAQ
What is Humacyte's price target?
The average analyst price target for Humacyte is $1.62, 278.8% above the latest close of $0.43.
Is Humacyte a buy, hold or sell?
Of 5 analysts covering Humacyte, 2 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Humacyte's EPS forecast?
Analysts forecast −$0.40 per share for 2026 (range −$0.46 to −$0.34); for 2027 the estimate is −$0.25.
What is Humacyte's revenue forecast?
The average revenue estimate for 2026 is $3.5 million, growth of 72.3%; for 2027 it is $21.7 million.
When does Humacyte report earnings?
Humacyte is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.09.
Does Humacyte usually beat earnings estimates?
Humacyte reported EPS at or above the analyst estimate in 6 of the last 12 quarters.